trial · primary record
Pembrolizumab
Clear Cell Renal Cell Carcinoma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1040 |
| Primary completion | 2037-11 |
| Primary endpoint | Disease-free survival (DFS) |
| Registry ID | NCT06661720 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:51.452Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06661720
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound